PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 95 filers reported holding PHATHOM PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $60 | -25.9% | 5,825 | +2.8% | 0.00% | – |
| Q2 2023 | $81 | -22.1% | 5,666 | -61.2% | 0.00% | – |
| Q1 2023 | $104 | -36.6% | 14,603 | 0.0% | 0.00% | – |
| Q4 2022 | $164 | -99.9% | 14,603 | -0.6% | 0.00% | – |
| Q3 2022 | $163,000 | +32.5% | 14,686 | +1.0% | 0.00% | – |
| Q2 2022 | $123,000 | -37.9% | 14,536 | -0.2% | 0.00% | – |
| Q1 2022 | $198,000 | -31.0% | 14,569 | 0.0% | 0.00% | – |
| Q4 2021 | $287,000 | -38.8% | 14,569 | -0.3% | 0.00% | – |
| Q3 2021 | $469,000 | -20.8% | 14,617 | -16.5% | 0.00% | -100.0% |
| Q2 2021 | $592,000 | +62.6% | 17,495 | +80.4% | 0.00% | – |
| Q1 2021 | $364,000 | +13.0% | 9,700 | 0.0% | 0.00% | – |
| Q4 2020 | $322,000 | -9.6% | 9,700 | 0.0% | 0.00% | – |
| Q3 2020 | $356,000 | +11.6% | 9,700 | 0.0% | 0.00% | – |
| Q2 2020 | $319,000 | +27.6% | 9,700 | 0.0% | 0.00% | – |
| Q1 2020 | $250,000 | -17.2% | 9,700 | 0.0% | 0.00% | – |
| Q4 2019 | $302,000 | – | 9,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 2,484,274 | $27,873,554 | 11.71% |
| Frazier Life Sciences Management, L.P. | 8,407,152 | $94,328,245 | 5.86% |
| Abingworth LLP | 1,435,106 | $16,101,889 | 5.25% |
| Opaleye Management Inc. | 417,500 | $4,684,350 | 1.63% |
| 683 Capital Management, LLC | 1,350,000 | $15,147,000 | 1.28% |
| Newtyn Management, LLC | 484,074 | $5,431,310 | 1.12% |
| Penn Mutual Asset Management | 62,802 | $704,638 | 0.79% |
| StepStone Group LP | 422,085 | $4,735,794 | 0.62% |
| MPM BioImpact LLC | 195,942 | $2,198,469 | 0.57% |
| Avidity Partners Management LP | 1,900,000 | $21,318,000 | 0.46% |